Real-World Outcomes of Ruxolitinib as Salvage Therapy in Steroid-Refractory Acute and Chronic Graft-Versus-Host Disease: A Multicenter Retrospective Observational Study from Turkey.

J Clin Med · 2026 · PMC12986514 · PMID 41827503

Europe PMC DOI

hedged sentence

0.0660

closest p · 1.3× alpha

0.0660

boldest claim

The sentences

borderline significancep = 0.066so close (0.05 < p ≤ 0.1)

Lack of response to ruxolitinib was associated with increased hazard with borderline significance (HR 2.64, 95% CI 0.94–7.42, p = 0.066), whereas age was not significant (HR 0.98 per year, 95% CI 0.95–1.02, p = 0.319).

also in 7,017 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.